Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
4TEEN4 Pharmaceuticals GmbH announced the closing of a EUR 6.9 million Series A financing round.
Fundraising will support the expansion of Hummingbird Bioscience’s discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics
Bpifrance and Pfizer Ventures co-led international investor syndicate
The company will further develop its high-resolution spinal cord stimulation focal pain therapy and perform clinical studies
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
Since its foundation Cambridge Innovation Capital has attracted £1 billion of investment into Cambridge companies, highlighting its dominant position at the heart of the innovation ecosystem
€8 million acquisition brings a wide range of revenue-generating products in orthopaedic, spine, dental and sports surgery
Proteros biostructures GmbH announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland.
Vivoryon Therapeutics AG, announced its third quarter business update for the period ending September 30, 2019.
Liminal BioSciences Inc. has announced that it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. (“PBL”) to KKR & Co., a leading global investment firm (“KKR”).